The combination of MET and PD-L1 inhibition shows promise in MET-induced metastatic papillary renal cell carcinoma.

Published Date: 02 Mar 2023

Advanced papillary kidney cancer (PRC) has a poor prognosis with few treatment options. About 30% of patients with this disease have mutations in the MET gene, which codes for hepatocyte growth factor.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

2.

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

5.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot